Introduction {#Sec1}
============

Australia has the highest prevalence of actinic keratoses (AK) worldwide affecting up to 60% of adults, especially elderly, fair-skinned men with outdoor lifestyles \[[@CR1], [@CR2]\]. AK are more common with age, chronic sun-exposure, and immunosuppressive drugs; regular sunscreen use is effective in preventing the development of AK \[[@CR3]\].

It is often desirable to treat AK to reduce the risk of progression to (in situ and) invasive squamous cell carcinoma (SCC) \[[@CR4]\]; improvement in associated symptoms and skin appearance are additional benefits of treatment. The various treatment options mainly include destructive therapies (e.g., cryosurgery, electrosurgery or excisional surgery), topical therapies (e.g., 5 fluorouracil, imiquimod, diclofenac, ingenol mebutate), photodynamic therapy (PDT) with photosensitising topical agent (e.g., methyl aminolevulinate cream; MAL), and combination therapies \[[@CR5]\]. Patient satisfaction with some treatments, especially destructive therapies, can be affected by considerable treatment discomfort and residual scarring.

A structured expert consensus statement on AK recently rated MAL DL-PDT as the preferred option for patients with multiple AKs on both small and large fields due to its efficacy and tolerability profile \[[@CR6]\]. Methyl aminolevulinate cream (Metvix^®^; Galderma) with red light \[conventional-PDT (c-PDT)\] is indicated for the treatment of thin or non-hyperkeratotic and non-pigmented AKs on the face and scalp, superficial and/or nodular basal cell carcinoma, and squamous cell carcinoma in situ (Bowen's disease). More recently, MAL DL-PDT has been approved in many countries for the treatment of face and scalp AK. In previous randomized, controlled, phase 3 studies conducted in Australia and Europe, MAL DL-PDT was demonstrated to be a simpler, less painful procedure with similar high efficacy and better safety compared to MAL c-PDT \[[@CR7], [@CR8]\]. In the Australian trial, MAL DL-PDT resulted in higher overall subject satisfaction compared to MAL c-PDT, with 100% of subjects satisfied to very satisfied with DL-PDT versus 85.7% for c-PDT \[[@CR7]\]. Similarly, in the European trial, 96.2% of subjects satisfied to very satisfied with DL-PDT (including 64.8% very satisfied) versus 83.1% (18.9% very satisfied) for c-PDT \[[@CR8]\].

For patients who require treatment of multiple AK that can easily be exposed to daylight, MAL DL-PDT may be particularly suitable, especially since there is sufficient daylight in Australia to use it throughout the year and during most weather conditions \[[@CR9]\].

The objective of this observational study was to generate real-life data on the use of MAL DL-PDT in clinical practice in Australia in the treatment of mild to moderate facial/scalp AK and to assess patient and physician satisfaction.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a prospective, observational study conducted in 6 centers in Australia between September 2015 and March 2016. Physicians experienced with MAL PDT (with red light) were invited to participate, and the prescription of MAL DL-PDT was at the sole discretion of the prescribing physician. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation-Good Clinical Practice principles and in compliance with local regulatory requirements. The study was reviewed and approved by the appropriate Independent Ethics Committees and written informed consent was obtained from all patients prior to study initiation. The study is registered at ClinicalTrials.gov identifier NCT02674048.

Patients {#Sec4}
--------

Eligible patients were aged 18 years or older and had been prescribed MAL DL-PDT as part of their routine medical care to treat mild to moderate AK on the face and/or scalp.

Treatment {#Sec5}
---------

A single treatment of MAL DL-PDT was administered.

Assessments {#Sec6}
-----------

At baseline, the number of AK lesions and the global severity of AK lesions were assessed by the physician. A follow-up visit for re-assessment as per clinical practice was proposed after 3 months, and efficacy was assessed on a 6-point global improvement scale from 1 (clear) to 6 (worse). After 3 months, patients completed questionnaires and each physician completed a questionnaire when all their study patients had completed the study. Post-treatment pain was assessed on a numerical rating scale from 0 (no pain) to 10 (extreme pain). Adverse events were recorded throughout the study.

Statistical Methods {#Sec7}
-------------------

All collected variables were descriptively summarized without replacement of any missing values (observed data only).

Results {#Sec8}
=======

Study Population {#Sec9}
----------------

A total of 81 patients were enrolled with a mean age of 62.7 years, the majority were male (76.5%) and all had skin phototype I (64.2%) or II (35.8%) (Table [1](#Tab1){ref-type="table"}). Among the patients who had received previous treatment for AK (93.8%), the mean duration of past treatments was 16.8 years. Almost all subjects (97.4%) were naïve to DL-PDT, with 2.6% and 18.4% of patients having received DL-PDT and c-PDT, respectively (Table [1](#Tab1){ref-type="table"}). All patients had multiple lesions, including 82.7% with \>10 lesions, and half the patients (49.4%) had \>20 lesions. Most patients (75.3%) had predominantly grade I lesions, which were mainly located over the full facial area (74.1% of patients) (Table [1](#Tab1){ref-type="table"}).Table 1Baseline demographic and clinical characteristicsPatients, *n* (%)\
*n* = 81Age (years) Mean ± SD62.7 ± 10.7Gender Male62 (76.5%)Skin phototype Type I52 (64.2%) Type II29 (35.8%)Previous AK treatment received76 (93.8%) Cryotherapy68 (89.5%) Fluorouracil47 (61.8%) Imiquimod30 (39.5%) Ingenol mebutate16 (21.1%) Conventional PDT14 (18.4%) Surgery13 (17.1%) Diclofenac8 (10.5%) Laser5 (6.6%) Peelings3 (3.9%) Daylight PDT2 (2.6%) Other2 (2.6%)Past medical history of AK treatments (years) Mean ± SD16.8 ± 10.4 Median (min--max)15.5 (1.0--43.0)Number of lesions \<53 (3.7%) 5--1011 (13.6%) 11--2027 (33.3%) \>2040 (49.4%)Global severity of the lesions Majority of grade I61 (75.3%) Majority of grade II11 (13.6%) Well balanced mix of grade I and II9 (11.1%)Grade III lesions present7 (8.6%)Location of lesions Entire face60 (74.1%) Scalp31 (38.3%) Forehead14 (17.3%) Nose9 (11.1%) Cheek8 (9.9%)*AK* actinic keratosis, *PDT* photodynamic therapy

The vast majority of patients (97.5%) completed the study and attended a follow-up visit at around 3 months.

The study physicians were experienced dermatologists (mean of 19 years clinical practice) regularly treating patients for AK (mean of 63 AK patients per week). The main reasons given by the physicians for using MAL DL-PDT treatment were treatment location (in 100% of patient cases), number of AK lesions (96.3%), efficacy to clear AK (96.3%), and because the area to be treated was large (95.1%) (Table [2](#Tab2){ref-type="table"}).Table 2Methyl aminolevulinate cream daylight photodynamic therapy (MAL DL-PDT) treatment procedurePatients, *n* (%)\
*n* = 81**Physician-provided data**Major consideration for choosing MAL DL-PDT Location of lesions81 (100%) Number of lesions78 (96.3%) Efficacy to clear AK78 (96.3%) Large area to be treated77 (95.1%) Tolerability72 (88.9%) Maintenance of AK clearance70 (86.4%) Patient adherence57 (70.4%) Cosmetic benefits41 (50.6%) Cost32 (39.5%)Preparation of skin before MAL application81 (100.0%) On entire field79 (97.5%) On lesions only2 (2.5%)Method of skin preparation Skin abrasive pad45 (55.6%) Microdermabrasion30 (37.0%) Curette28 (34.6%) Other^a^7 (8.6%)Sunscreen applied69 (85.2%) After skin preparation before MAL36 (52.2%) Before skin preparation32 (46.4%) After MAL1 (1.4%)Location of MAL application On entire field80 (98.8%) On lesions only1 (1.2%)Time between MAL application and daylight exposure (min) (*n* = 53) Mean ± SD6.2 ± 4.7 Min--max0--20Time of daylight exposure (h) (*n* = 53) Mean ± SD2.0 ± 0.1 Min--Max1.8-2.5Post-treatment care recommended81 (100.0%) Moisturizer80 (98.8%) Sunscreen78 (96.3%) Cleanser77 (95.1%)**Patient-provided data**Weather during daylight exposure (*n* = 78) Sunny46 (59.0%) Mixed sunny/cloudy24 (30.8%) Cloudy8 (10.3%)Temperature during daylight exposure (*n* = 80) 15--20 °C7 (8.8%) 20--25 °C29 (36.3%) 25--30 °C37 (46.3%) \>30 °C7 (8.8%)Time spent in the shade51 (63.0%) Mean time in the shade ± SD (min) (*n* = 51)44.3 ± 41.7MAL removed after daylight exposure (*n* = 80)71 (88.8%)*AK* actinic keratosis, *MAL* methyl aminolevulinate cream, *DL*-*PDT* daylight photodynamic therapy^a^More than one method could be used and *other* were heavy gauze and gauze with scraping

MAL DL-PDT Procedure {#Sec10}
--------------------

The entire field was prepared before the MAL cream application in the vast majority of patients (97.5%), mainly using a skin abrasive pad (55.6%), microdermabrasion (37%) and/or curettage of individual lesions (34.6%) (Table [2](#Tab2){ref-type="table"}). Sunscreen was applied in most cases (85.2%) with about half (46.4%) applying sunscreen before skin preparation and about half (52.2%) after skin preparation. In almost all cases (98.8%), MAL cream was applied to the entire field. Patients spent a mean duration of 2 h outside in the daylight. Post-treatment skin care was recommended to all patients, especially moisturizer, sunscreen and/or cleanser. According to the patient questionnaire results, the weather was mainly sunny in most cases (59%) and almost two-thirds of patients (63%) spent some time in the shade (Table [2](#Tab2){ref-type="table"}).

Efficacy {#Sec11}
--------

In this patient population with multiple lesions, almost half of the patients (46.8%) required no further treatment at month 3 and physician-assessed global improvement at 3 months graded the vast majority of patients (88.6%) as at least much improved. Of the patients requiring re-treatment at 3 months, the most frequently received treatment was cryotherapy (88.1%) for a few residual lesions.

Patient Satisfaction {#Sec12}
--------------------

Most patients (79.7%) were overall satisfied or very satisfied with the treatment when questioned at 3 months (Fig. [1](#Fig1){ref-type="fig"}). Most patients were satisfied or very satisfied with the effectiveness of the MAL DL-PDT treatment and with the appearance of the treated area of their skin (77.2% and 75.9%, respectively) (Fig. [2](#Fig2){ref-type="fig"}). Of the patients who had previously been treated for AK, 7 out of 10 (68.2%) considered that MAL DL-PDT was better than their previous treatment (Fig. [3](#Fig3){ref-type="fig"}a). Overall, 8 out of 10 patients (80.8%) would consider using MAL DL-PDT again (Fig. [3](#Fig3){ref-type="fig"}b).Fig. 1Overall satisfaction with daylight-activated methyl aminolevulinate treatment according to patient and physician questionnaires at end of study Fig. 2Patient satisfaction with the treatment effectiveness and the appearance of their treated skin at end of study Fig. 3Patient responses when asked **a** How does daylight-activated methyl aminolevulinate compare with your last treatment for actinic keratosis? **b** Would you use daylight-activated methyl aminolevulinate again? and **c** How bothered were you by any pain?

Physician Satisfaction {#Sec13}
----------------------

Overall, physicians were satisfied/very satisfied (83.3%) with the treatment at the end of the study (Fig. [1](#Fig1){ref-type="fig"}), and all physicians indicated that they would use MAL DL-PDT treatment again in the future.

Safety {#Sec14}
------

After receiving the treatment at baseline, the mean pain level was very low at 1.6 on a 0--10 scale and 74.1% of patients indicated in the patient questionnaire that they were not bothered at all by pain (Fig. [3](#Fig3){ref-type="fig"}c).

Related AEs were reported in nearly half (48.1%) of patients, most frequently mild erythema (44.4%). No event was assessed as serious by the investigators during the study, but one related AE (SCC) was reclassified as serious by the sponsor. All other AEs were mild except for one patient with moderate skin exfoliation at month 3 and one patient who experienced severe related phototoxic reactions post-treatment (erythema, pain of skin, photosensitivity reaction, pruritus, skin burning sensation, skin irritation) that resolved within 4 days of intensive moisturizer use.

Most patients (69.3%) indicated they were not bothered at all by side effects, and the mean duration of downtime due to skin reactions was only 3.6 days. At the end of the study, all the physicians (100%) indicated they were satisfied with the tolerability of MAL DL-PDT.

Discussion {#Sec15}
==========

In this observational study, 80% of patients were satisfied or very satisfied with the MAL DL-PDT treatment, and this was despite the fact that MAL DL-PDT is not reimbursed in Australia. In a randomized, controlled trial in Australia in a similar patient population (mean age 66.9 years, 75% men) with a high number of lesions at baseline (mean 14.8), albeit mostly mild lesions, the overall patient satisfaction was even higher, with all subjects either satisfied (50%) or very satisfied (50%) \[[@CR7]\].

In these patients with a long history of AKs, but mostly naïve to MAL DL-PDT (97%), factors that may have contributed to the high patient and physician satisfaction include the convenient single treatment session, short time to healing, high tolerability and low pain, as well as the excellent cosmetic outcome and good efficacy. Despite a high number of AK at baseline, 47% of patients required no further treatment 3 months after a single session of MAL DL-PDT, and those patients requiring further treatment at month 3 were mainly treated by cryotherapy (88%) for a few residual lesions.

In the vast majority of cases, the entire field (98%) was prepared before application of the MAL cream to the entire field (99%), as recommended by the Australian MAL DL-PDT consensus recommendations \[[@CR10]\]. In patients with multiple lesions over large areas, field-directed therapy is appropriate given the importance of treating both clinically visible and subclinical lesions \[[@CR11], [@CR12]\]. Pretreatment of hyperkeratosis before application of the MAL cream was carried out exclusively by mechanical methods, with no reports of chemical methods (more than one method could be used). A previous study with c-PDT demonstrated that, although urea or salicylic acid had similar efficacy to curettage, the tolerability was slightly lower with more pain and higher rates of erythema \[[@CR13]\].

The MAL DL-PDT procedure was well tolerated and almost painless, with 74% of patients indicating they were not bothered at all by any pain. This is quite remarkable since the treated areas were very large and the entire face was affected in 74% of patients. Related AEs were mostly mild skin reactions that resolved rapidly, and over two-thirds of patients (69%) indicated that they were not bothered at all by side effects. One serious AE of SCC was reported, which highlights the importance of investigating suspicious lesions at baseline and closely following up high-risk patients, especially those with a long history of AK, previous history of non-melanoma skin cancer and high number of lesions at baseline. Local immunosuppression induced by PDT (with aminolevulinic acid or MAL) has been described in healthy human volunteers \[[@CR14]\], albeit a reduced risk was observed with lower light intensities (such as daylight) \[[@CR15]\]. However, treating patients with AK and skin cancers is a different situation than healthy skin. In skin cancers, PDT may stimulate the immune response resulting in high efficacy \[[@CR16]\], possibly by attracting host leukocytes into the tumor and increasing antigen presentation \[[@CR17]\], or through systemic, antigen-specific anti-tumor immunity \[[@CR18], [@CR19]\]. A 24-week randomized, controlled trial conducted in Australia with MAL DL-PDT reported no serious AEs over the entire study period, and 79% of patients reported they were not bothered at all by side effects \[[@CR7]\].

Limitations of this study are the non-interventional nature and lack of a control group. However, the results are consistent with those from a randomized controlled trial conducted in 7 investigational centers in Australia \[[@CR7]\].

Conclusion {#Sec16}
==========

This real-life observational study confirms that MAL DL-PDT is used in the treatment of diagnosed AK according to Australian MAL DL-PDT consensus recommendations. The results provide evidence supporting the high levels of patient and physician satisfaction, as well as good efficacy and tolerability, of MAL DL-PDT for the treatment of multiple mild to moderate non-hyperkeratotic AK of the face and/or the scalp.
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